After moving from Sierra Leone to London, guest columnist Richard Bayliss received a proper diagnosis and care plan for his sickle cell.

Richard Bayliss is 44 years old and has sickle cell disease with hemoglobin SS disease. He’s in the final year of a master’s ...

In 2019, the first CRISPR clinical trials were conducted to treat sickle cell diseases and in 2020, this treatment was ...

As is the case for institutions treating the disease, a majority of the sickle cell patients at SSM Health Cardinal Glennon Children’s Hospital are African American. The hospital recognized the need ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

The new gene therapies for sickle cell disease—including the gene-editing treatment Casgevy, based on research at Boston Children's Hospital—have been game-changing for the patients who have ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

Adults with sickle cell anemia (SCA) and healthy controls with greater economic deprivation have older brain age.

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...

Asiawu Imam says the therapy will make a huge difference A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England.

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely ...